Assuntos
Anti-Infecciosos/uso terapêutico , Ciprofloxacina/uso terapêutico , Tularemia/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Francisella tularensis/imunologia , Francisella tularensis/isolamento & purificação , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Tularemia/microbiologiaRESUMO
We present a case of primary costochondritis by Escherichia coli, in a diabetic woman. The patient suffered a urinary infection by E. coli which may have been the source of haematogenous spread. She received medical and surgical therapy and 5 months later, she was asymptomatic.
Assuntos
Infecções por Escherichia coli/complicações , Síndrome de Tietze/etiologia , Idoso , Feminino , HumanosRESUMO
BACKGROUND: Pyomyositis is a purulent infection involving the skeletal muscle. Although it was initially described in tropical countries, is it ever more frequently found in warm climates. METHODS: A review of the clinical histories of the admission of patients in the Internal and Infectious Medicine Units over the period from May 1992 to April 1994 (1818 admissions) was carried out analyzing those in whom the diagnosis was of pyomyositis. This diagnosis was performed by clinical data and radiologic and microbiologic confirmation. RESULTS: Five patients diagnosed with pyomyositis were found. Of the five cases, four were men with ages ranging from 27 to 64 years. In most of the cases more than one muscle group was involved and only two cases showed predisposing factors (history of injury and DM). The existence of abscesses was shown by echography in 3 cases and by CAT in 2 cases. Staphylococcus aureus was the most frequently isolated microorganism. The five patients underwent medical treatment and surgical treatment was also performed in 2 achieving satisfactory evolution. CONCLUSIONS: Imaging techniques (echography and CAT) effectively contribute to the diagnosis of pyomyositis. Medical treatment, associated with surgery in some cases, achieved satisfactory evolution. The incidence of pyomyositis is probably greater than what has been recognized to date.
Assuntos
Miosite/microbiologia , Infecções Estafilocócicas , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Miosite/diagnóstico por imagem , Gravidez , Estudos Retrospectivos , Staphylococcus aureus/isolamento & purificação , Supuração/microbiologia , UltrassonografiaRESUMO
A pilot study has been designed in order to determine the tolerance and effectiveness of recombinant interferon gamma (rIFN-gamma) in chronic hepatitis B virus (HBV) infection. Eight HBsAg, HBeAg, HBV-DNAp and HBV-DNA-positive patients were randomly assigned to one of two groups. In group 1, 0.25 mg of rIFN-gamma/m2 body surface was administered daily for 28 days to 4 patients. In group 2, 0.10 mg of rIFN-gamma was administered to 4 patients under the same conditions. All the patients concluded the treatment and were observed over 11 more months. During treatment, 6 out of 8 patients showed decreased levels of HBV-DNA and HBV-DNAp. In addition, by the 8th month of follow-up, six patients became negative for HBV-DNAp and 2 for HBcAg; all patients remained positive for HBV-DNA. At the end of the study, only 2 patients remained negative for HBV-DNAp, 4 for HBcAg and one became negative for HBV-DNA. No differences in antiviral effect were observed between the two groups. Furthermore, the T4/T8 lymphocytes ratio increased during therapy. In conclusion, rIFN-gamma may play a role in the treatment of chronic HBV infection.
